WuXi XDC Cayman Inc.
WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufacture of the drug substances and drug products of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associa… Read more
WuXi XDC Cayman Inc. (L74) - Net Assets
Latest net assets as of June 2025: €7.44 Billion EUR
Based on the latest financial reports, WuXi XDC Cayman Inc. (L74) has net assets worth €7.44 Billion EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€10.62 Billion) and total liabilities (€3.18 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €7.44 Billion |
| % of Total Assets | 70.06% |
| Annual Growth Rate | 582.24% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 3229.03 |
WuXi XDC Cayman Inc. - Net Assets Trend (2021–2024)
This chart illustrates how WuXi XDC Cayman Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for WuXi XDC Cayman Inc. (2021–2024)
The table below shows the annual net assets of WuXi XDC Cayman Inc. from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €6.64 Billion | +21.73% |
| 2023-12-31 | €5.45 Billion | +268.34% |
| 2022-12-31 | €1.48 Billion | +6991.51% |
| 2021-12-31 | €20.88 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to WuXi XDC Cayman Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 7017.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €1.43 Billion | 21.58% |
| Other Components | €5.21 Billion | 78.42% |
| Total Equity | €6.64 Billion | 100.00% |
WuXi XDC Cayman Inc. Competitors by Market Cap
The table below lists competitors of WuXi XDC Cayman Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sumitomo Rubber Industries Ltd
F:108
|
$2.11 Billion |
|
Indra Sistemas S.A
OTCGREY:ISMAF
|
$2.11 Billion |
|
OliX PharmaceuticalsInc
KQ:226950
|
$2.11 Billion |
|
Oberbank AG
VI:OBS
|
$2.11 Billion |
|
NBT Bancorp Inc
NASDAQ:NBTB
|
$2.11 Billion |
|
Wuchan Zhongda Group Co Ltd
SHG:600704
|
$2.11 Billion |
|
Zabka Group S.A.
WAR:ZAB
|
$2.10 Billion |
|
Camurus AB (publ)
OTCGREY:CAMRF
|
$2.10 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in WuXi XDC Cayman Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 5,454,316,000 to 6,639,489,000, a change of 1,185,173,000 (21.7%).
- Net income of 1,069,622,000 contributed positively to equity growth.
- New share issuances of 3,637,000 increased equity.
- Other factors increased equity by 111,914,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €1.07 Billion | +16.11% |
| Share Issuances | €3.64 Million | +0.05% |
| Other Changes | €111.91 Million | +1.69% |
| Total Change | €- | 21.73% |
Book Value vs Market Value Analysis
This analysis compares WuXi XDC Cayman Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.09x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 341.44x to 1.09x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €0.02 | €6.05 | x |
| 2022-12-31 | €1.26 | €6.05 | x |
| 2023-12-31 | €4.55 | €6.05 | x |
| 2024-12-31 | €5.53 | €6.05 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently WuXi XDC Cayman Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 16.11%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 26.40%
- • Asset Turnover: 0.44x
- • Equity Multiplier: 1.37x
- Recent ROE (16.11%) is below the historical average (73.72%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 263.06% | 17.65% | 0.35x | 42.13x | €52.84 Million |
| 2022 | 10.52% | 15.72% | 0.40x | 1.69x | €7.65 Million |
| 2023 | 5.20% | 13.35% | 0.32x | 1.23x | €-261.89 Million |
| 2024 | 16.11% | 26.40% | 0.44x | 1.37x | €405.67 Million |
Industry Comparison
This section compares WuXi XDC Cayman Inc.'s net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $12,122,986,067
- Average return on equity (ROE) among peers: -39.65%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| WuXi XDC Cayman Inc. (L74) | €7.44 Billion | 263.06% | 0.43x | $2.11 Billion |
| Spermosens AB (publ) (9R5) | $23.64 Million | -27.17% | 0.09x | $517.28K |
| BML Inc (BMZ) | $81.13 Billion | 8.19% | 0.43x | $462.01 Million |
| Genomic Vision Société Anonyme (G09) | $3.07 Million | -162.85% | 1.21x | $711.54K |
| ICON Public Limited Company (IJF) | $1.85 Billion | 17.96% | 0.86x | $6.43 Billion |
| Adicon Holdings Limited (K0U) | $1.77 Billion | 2.65% | 1.64x | $138.53 Million |
| NanoRepro AG (NN6) | $57.61 Million | 51.59% | 0.37x | $16.84 Million |
| PERRIGO (PGO) | $24.67 Million | -167.93% | 0.99x | $6.37K |